From Crash to Breakthrough: Why Lunai Bioworks (LNAI) Is Suddenly on Investors’ Radar
Company Overview: AI-Powered Biotech at the Intersection of Therapeutics & Biodefense Lunai Bioworks Inc. is a pre-clinical stage biotechnology company pioneering an unusual dual focus: AI-driven drug discovery and biodefense. The company’s mission is to “capture biological signals at scale, decode them with AI, and rapidly validate insights in model systems”, bridging cutting-edge computation with experimental biotechainvest.comainvest.com. In practical terms, Lunai is developing both therapeutic platforms (for diseases like cancer and neurodegeneration) and advanced diagnostics/screening tools (including detecting chemical/biological threats), all underpinned by machine learning. Core Technology & Pipeline: Lunai’s flagship approach is a next-generation allogeneic dendritic cell (DC) therapy
